Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 5:43 PM
Ignite Modification Date:
2025-12-24 @ 5:43 PM
NCT ID:
NCT01117168
Eligibility Criteria:
* All patients, diagnosed with a primary malignancy since the date the initial IRB approval was received for this study with any of the following diagnoses are eligible:
* All cancer cases with an ICD-O histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant).
* All lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant.
* The benign/borderline conditions which will be reportable by agreement shall include:
* Mesoblastic nephroma.
* All teratomas, regardless of locations.
* Myeloproliferative disease
* Langerhans Cell histiocytosis
* Patients with a secondary malignancy may be eligible provided they also meet the criteria in the above. These patients need to be enrolled using their primary diagnosis.
* Participants 0 through 21 years of age are eligible; irrespective of eligibility for other COG studies.
* Participant must be resident of the United States, Canada or Mexico.
Healthy Volunteers:
False
Sex:
ALL
Maximum Age:
21 Years
Study:
NCT01117168
Study Brief:
Protocol Section:
NCT01117168